Fortekor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fortekor

What is Fortekor?

Fortekor is a veterinary medication used primarily in the management of heart failure in dogs and chronic kidney disease in cats. It belongs to a class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. The active ingredient in the medication is benazepril hydrochloride.

Mechanism of Action

As an ACE inhibitor, benazepril acts as a prodrug that is converted by the liver into its active form, benazeprilat. This active metabolite works by inhibiting the enzyme responsible for converting angiotensin I into angiotensin II.

Angiotensin II is a potent substance in the body that causes blood vessels to narrow and promotes the retention of salt and water. By reducing the production of angiotensin II, the medication helps to:

  • Lower blood pressure: By allowing blood vessels to relax and widen (vasodilation).
  • Reduce workload on the heart: By decreasing the pressure the heart must pump against, which is particularly beneficial for dogs with congestive heart failure.
  • Protect kidney function: By reducing the pressure within the filtration units of the kidneys (glomeruli), which helps to decrease the loss of protein into the urine in cats with chronic renal insufficiency.

Therapeutic Use in Animals

In canine medicine, the medication is frequently utilized to manage clinical signs associated with heart failure, such as exercise intolerance or coughing. By improving cardiovascular efficiency, it aims to enhance the animal's quality of life.

In feline medicine, the focus of the medication is often on managing chronic kidney disease. While it does not cure the underlying condition, it is used to help stabilize kidney function and manage systemic hypertension often associated with renal issues.

Regulatory References

  1. Benazepril Monograph - DailyMed - NIH

What side effects are possible with Fortekor?

Possible Side Effects and Safety Information

The safety profile for Fortekor (Benazepril) is based strictly on classifications found in official governmental regulatory documents. The majority of documented adverse reactions are categorized by regulatory authorities as rare or very rare.

Frequency-Classified Adverse Reactions

The documented side effects primarily affect the Gastrointestinal Tract and include signs such as diarrhea, vomiting, and anorexia (loss of appetite), which are classified as rare (occurring in 1 to 10 animals per 10,000 treated). Fatigue and lethargy are also noted in this frequency band. Less frequently, reactions like incoordination or changes in weight and appetite are categorized as very rare (occurring in less than 1 per 10,000 treated).

Safety Considerations and Restrictions

The regulatory label identifies specific safety patterns and constraints. For patients with Chronic Kidney Disease (CKD), a transient, moderate increase in plasma creatinine concentrations may be observed at the start of therapy, which is an expected finding in this population. Certain side effects, such as vomiting and fatigue, are noted to be transient (short-lived).

Use of Benazepril is contraindicated in specific circumstances, including pre-existing conditions like hypotension (low blood pressure), hypovolemia (low blood volume), or hyponatremia (low blood sodium levels). Furthermore, the medicine is contraindicated during pregnancy and lactation due to documented risks.

High-level safety notes include the potential for additive hypotensive effects when the medicine is used concurrently with other anti-hypertensive agents, and an increased risk of hyperkalemia when combined with potassium-sparing diuretics.

Overdose and Emergency Response

The official regulatory documentation for Benazepril (Fortekor) defines the primary risk of overdose as the acute and expected physiological effect of the medication: transient reversible hypotension (low blood pressure). This manifestation of excessive ACE inhibition may be clinically apparent through associated signs such as lethargy and generalized weakness, as noted in the official label.

Overdose is classified as a serious event due to the potential for excessive hypotension to lead to dangerously low blood pressure or contribute to conditions such as acute renal failure.

Required Emergency Actions

In the event of an overdose or accidental exposure, immediate help-seeking is mandated. Accidental human ingestion requires showing the product label to a physician and seeking medical advice immediately. For animal overdose, contacting a veterinarian or an animal poison control center is the required course of action.

Management and Monitoring

No specific antidote is known for Benazepril overdose; therefore, management must be symptomatic and supportive. The officially described procedure for treating severe hypotension is the intravenous infusion of warm isotonic saline.

Special regulatory warnings indicate that pregnant women should take specific care to avoid accidental oral exposure to the medication due to the documented risks associated with ACE inhibitors.

Therapeutic Uses of Fortekor

What Fortekor Treats: Main Uses and Benefits

Fortekor is relevant in clinical settings marked by conditions associated with acute or disruptive episodes, offering supportive relief for pets managing chronic conditions. The medication is commonly used in two primary therapeutic areas: supporting canine patients with Congestive Heart Failure (CHF) and assisting feline patients with Chronic Kidney Disease (CKD).


Therapeutic Focus & Benefits

In heart failure, the medication is generally applied in scenarios where additional symptomatic support is needed to help manage symptom clusters that may become intense or disruptive, such as distressing coughing and breathing difficulties that interfere with daily functioning. In kidney disease, it assists in addressing signs linked to organ-specific functional stress, most critically proteinuria. In these situations, the medication supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Support for Symptom Management

Primary Use Domain Symptom Axis Supported
Canine Heart Support Symptoms related to systemic imbalance and respiratory strain
Feline Kidney Support Symptoms linked to organ-specific functional stress

Regulatory References

  1. Veterinary Medicines Directorate (VMD) official product information

Eligibility and Restrictions for Use

The eligibility profile for Fortekor (Benazepril hydrochloride) is strictly defined by regulatory documents, specifying the populations that can and cannot use the veterinary medicine.

Who Must Not Use Fortekor (Contraindications)

Use of this medicine is absolutely prohibited in several populations. These contraindications include known hypersensitivity to Benazepril or its components, as well as cases of pre-existing hemodynamic instability, such as hypotension (low blood pressure), hypovolemia, or hyponatremia (low sodium levels). Fortekor is also strictly contraindicated in patients with acute renal failure or conditions causing reduced cardiac output, such as aortic or pulmonary stenosis.

Restricted and Not-Established Use

The regulatory label imposes restrictions based on life stage and size. The medicine is not established for dogs and cats weighing less than 2.5 kg body weight. Furthermore, Fortekor is not recommended for use during pregnancy or lactation because its safety has not been formally established for these life stages. For its approved use in cats with Chronic Kidney Disease, the label permits use but mandates conditional monitoring, requiring regular assessment of blood parameters, including plasma creatinine, urea, and erythrocyte counts.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe specific considerations when Fortekor is administered concurrently with other medicinal products. These interactions primarily involve effects on blood pressure and kidney function.

Combinations Requiring Close Monitoring or Caution

Interacting Product Category Official Constraint or Requirement
Other Anti-hypertensive Agents (e.g., calcium channel blockers, diuretics) May lead to additive hypotensive effects. Caution and monitoring are advised.
Anaesthetics and Sedatives Concomitant use may result in additive hypotensive effects, necessitating close observation.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Use requires caution due to regulatory concerns about potential reduced anti-hypertensive efficacy and impaired kidney function. Close monitoring of kidney function is recommended.
Potassium-Sparing Diuretics (e.g., spironolactone) Monitoring of plasma potassium levels is recommended because the combination may increase the risk of hyperkalaemia (high blood potassium).

Combinations With No Demonstrated Adverse Interaction

In clinical studies focused on congestive heart failure, Fortekor has been administered in combination with specific anti-arrhythmic products, digoxin, and pimobendan without any documented adverse interactions. The overall interaction profile is structured to ensure that combinations presenting a risk of altered blood pressure or electrolyte balance are appropriately managed with explicit monitoring requirements.

Mechanism of Action

Fortekor (benazepril) operates as a prodrug that is metabolized into its active form, benazeprilat. Benazeprilat is an Angiotensin-Converting Enzyme (ACE) inhibitor that acts by competitively binding to and blocking the ACE enzyme. This enzymatic blockade occurs predominantly on the surface of vascular endothelial cells.

This mechanism prevents the conversion of the precursor hormone Angiotensin I into the vasoconstrictor Angiotensin II, thereby modulating the entire Renin-Angiotensin-Aldosterone System (RAAS) cascade. The resulting reduction in Angiotensin II concentration diminishes both systemic vasoconstrictive stimuli and the Angiotensin II-mediated stimulus for Aldosterone release.

At a cellular level, suppression of Angiotensin II signaling influences molecular cascades that determine tissue architecture. This action modulates the signaling pathways that promote hypertrophy and fibrosis within cardiovascular structures.

Dosage and Administration Information

The administration of Fortekor, which contains Benazepril hydrochloride, utilizes the oral route as the method of delivery. The medication is provided as a scored tablet, allowing for division to ensure precise, weight-based dosing. The standard schedule for the drug, regardless of the indication, is once daily, and the treatment duration is considered unlimited for the long-term management of chronic conditions.

Dosing is determined based on the patient's body weight (mg/kg) and species. For canine patients with congestive heart failure, the initial minimum starting dose is 0.25 mg/kg body weight once per day. This dosage may be doubled to 0.5 mg/kg body weight once daily. For feline patients managing chronic kidney disease, the minimum dose is 0.5 mg/kg body weight once per day.

The administration process allows for flexibility, as the medicine can be given with or without food. No dose adjustment is necessary for patients with renal insufficiency, as the active metabolite is eliminated via balanced biliary and urinary routes. The scored nature of the tablet enables accurate halving, though any unused half tablet must be returned to the open blister and stored for no more than two days. Furthermore, the efficacy and safety profile is not established for animals weighing less than 2.5 kg.

Recent Clinical Evidence

Fortekor: Recent Clinical Evidence

The evidence base for Benazepril (the active ingredient in Fortekor) primarily relies on randomized, controlled clinical trials (RCTs). These authoritative studies compare the study cohort against an inactive treatment (placebo) or a defined control group under strict, monitored conditions. These studies contribute to the broader evidence landscape that regulatory bodies consider when assessing the medicine's defined scope.


Canine Congestive Heart Failure (CHF)

The research conducted on Benazepril for canine patients involved long-term, multicenter, placebo-controlled trials. These studies were used in research exploring how symptoms change over time in dogs with CHF. The primary research focus was the examination of long-term outcomes, including measuring survival time and time elapsed before the heart condition reached a defined endpoint.

Controlled clinical trials reported differences in median survival time when comparing the study cohort against the placebo cohort. Research also monitored outcomes related to physical discomfort and systemic imbalance, specifically tracking changes in clinical signs like cough frequency and measures of patient activity over the observation periods.


Feline Chronic Kidney Disease (CKD)

For feline patients, controlled clinical trials examined the use of Benazepril in cats with CKD, particularly those presenting with high levels of protein in their urine (proteinuria). The main focus was measuring the change in the Urine Protein-to-Creatinine Ratio (UPC), a key outcome related to physiological stress on the kidneys.

Studies monitored how the measured UPC ratio evolved over defined time intervals compared to the control group. However, findings were mixed when studies explored whether the use of Benazepril monotherapy was associated with a statistically significant difference in overall renal survival time when compared to a placebo in the full study population of CKD cats.


Research Gaps and Uncertainty

Research has explored outcomes across different subgroups, but data are still emerging for certain populations, such as dogs with Dilated Cardiomyopathy (DCM) or cats with advanced, late-stage CKD. Furthermore, the research identifies the primary measured outcome (proteinuria reduction) as a surrogate endpoint. Therefore, certainty remains low regarding the definitive long-term survival effects in the absence of additional research, as results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Fortekor (FAQ)


Q: Is Fortekor the same as other medicines for high blood pressure?

Fortekor contains the active ingredient Benazepril, which is part of the Angiotensin-Converting Enzyme (ACE) inhibitor class of medicines. While this class is recognized for managing blood pressure and fluid retention, its function is distinct from other types of blood pressure medications. Official product information categorizes it based on its specific mechanism of action within the body’s circulatory system.


Q: How quickly does Fortekor start to show an effect?

Studies on the medicine's activity show that its active form, Benazeprilat, reaches its highest concentration in the body rapidly, typically within one to two hours after administration. This leads to enzyme inhibition that is designed to be long-lasting, consistent with the standard once-daily administration schedule defined in the product documents.


Q: What happens if I forget to take Fortekor for one day?

Regulatory guidance for missed doses often suggests taking the dose as soon as the lapse is noticed. However, if it is already close to the time of the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Official guidance includes the explicit warning not to take a double dose to compensate for the missed one.


Q: Is Fortekor a diuretic (water pill)?

No, Fortekor is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. It works indirectly on fluid balance by reducing the action of a hormone called Aldosterone, which helps to lessen sodium and water retention. While it impacts fluid levels, its primary function and classification differ from that of a conventional diuretic (water pill).


Q: What should be done if a user takes more Fortekor than described?

In regulatory documents, an overdose is primarily associated with transient reversible hypotension, which is low blood pressure. This may present as temporary weakness or lethargy. Management described in regulatory documents primarily addresses the resulting hypotension through supportive measures and close monitoring of body parameters, such as electrolyte balance.


Q: Is Fortekor known to cause drowsiness or fatigue?

Official safety data lists fatigue (tiredness) and lethargy (sluggishness) as rare adverse reactions observed in clinical trials. Drowsiness (somnolence) has also been noted as a potential reaction associated with the broader class of ACE inhibitor medicines.


Q: What are the most commonly reported side effects of Fortekor?

The side effects documented in official regulatory sources as rare (occurring in 1 to 10 out of every 10,000 cases treated) primarily involve the Gastrointestinal Tract. These include signs such as diarrhea, vomiting, and anorexia (loss of appetite), along with general fatigue and lethargy.


Q: Is it common to feel dizzy when starting Fortekor?

Dizziness is a possible effect of medications that lower blood pressure, such as those in the ACE inhibitor class. This symptom may be more noticeable when starting the medication or when the dose is increased, although specific dizziness is not listed as a frequent side effect in the core product label.


Q: Are there any long-term health concerns with taking Fortekor?

Fortekor is officially described as a long-term treatment, and the regulatory label specifies that the treatment duration is considered unlimited for managing chronic conditions. Studies focus on the long-term effectiveness of the medicine in areas like survival time and proteinuria reduction, indicating it is an established therapy intended for ongoing management.


Q: What is the typical timeframe for a user to adjust to Fortekor?

Official information indicates that some side effects, such as vomiting or fatigue, are usually transient (short-lived). The active drug in the body reaches a stable level, known as a steady state, generally within a few days of consistent use.


Q: Does Fortekor interact with painkillers like ibuprofen?

Official documents caution that the use of Fortekor with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes ibuprofen, requires monitoring. The combination is noted in official sources for its potential to lead to reduced treatment efficacy and possible changes in kidney function.


Q: Can a person stop taking Fortekor suddenly?

Fortekor is intended for the long-term management of chronic conditions. Discontinuation should not occur abruptly, as stopping the medicine may allow the underlying condition that it is treating to worsen.


Q: Is Fortekor available in different strengths?

Yes, regulatory product information confirms that Fortekor (Benazepril hydrochloride) is officially supplied in multiple strengths, which often include 2.5 mg, 5 mg, and 20 mg tablets, to allow for flexible administration based on body weight and prescribed needs.


Q: Why are regular blood tests sometimes needed while taking Fortekor?

Regular blood monitoring, including plasma creatinine, urea, and erythrocyte counts, may be necessary for patients with chronic kidney disease or when Fortekor is used alongside other specific interacting medications. The purpose of this monitoring is to track kidney function and potential changes in electrolyte levels.


Q: What is the connection between Fortekor and potassium levels?

The mechanism of Fortekor influences the system that manages sodium and potassium balance in the body. The combination with specific Potassium-Sparing Diuretics is explicitly noted to increase the risk of hyperkalemia (high blood potassium). This means monitoring of plasma potassium levels is recommended when these two types of medicines are used concurrently.


Q: Does Fortekor affect the liver or kidney function?

Fortekor is metabolized by the liver into its active form. Regarding the kidneys, a temporary and expected increase in plasma creatinine may occur when starting therapy in patients with chronic kidney disease. General liver dysfunction has been reported in rare instances for medicines in this class.


Q: Are there any known interactions between Fortekor and alcohol consumption?

Official information regarding the ACE inhibitor class notes that combined use with alcohol may result in a greater overall reduction in blood pressure. This potential additive effect can lead to symptoms such as lightheadedness, dizziness, or fainting.


Q: What are the signs that Fortekor is working?

The effects of Fortekor are tied to its approved uses. In managing heart conditions, its action helps to ease the volume load on the heart. For specific chronic kidney issues, research focuses on whether the medication leads to a reduction in proteinuria (excess protein in the urine).


Q: Does Fortekor affect blood sugar levels?

Although not a primary action of the drug, the broader class of ACE inhibitors has been associated with reported variations in laboratory results, including occasional elevations of blood glucose.


Q: Can Fortekor be crushed or split if swallowing is difficult?

The Fortekor tablet is manufactured as a scored tablet, which is designed to be accurately divided (split) to facilitate precise, weight-based dosing. However, any divided tablet must be used quickly; the unused half must be returned to its blister pack and stored for a very limited time (e.g., 1–2 days) to maintain its stability.


Q: How long does the effect of one dose of Fortekor typically last?

Official pharmacological data indicates that Fortekor’s design provides a long-lasting inhibition of the target enzyme. Significant activity persists for 24 hours after a single dose. This duration is consistent with the product’s intended once-daily administration schedule.


Q: Is Fortekor a type of beta-blocker?

No, Fortekor is classified within the pharmacological group known as Angiotensin-Converting Enzyme (ACE) inhibitors. This classification is based on its specific mechanism of action, which is distinct from that of beta-blocker medicines.


Q: Does Fortekor cause a persistent cough like some other medicines in its class?

A dry, persistent cough is a recognized, though not universal, side effect associated with the class of ACE inhibitor medicines. The core product label for Fortekor does not list cough as a frequent adverse reaction, but the possibility exists due to the drug class's action.


Q: Does Fortekor interact with common cold or flu medications?

Caution is advised because many common cold and flu medicines contain ingredients such as NSAIDs (e.g., aspirin) or decongestants. Official warnings indicate that NSAIDs may reduce the effectiveness of blood pressure treatments and could potentially impact kidney function.


Q: What is the relationship between Fortekor and swelling (edema)?

The way Fortekor works on the Renin-Angiotensin-Aldosterone System (RAAS) helps to reduce the retention of sodium and water in the body, which can alleviate fluid accumulation (edema). However, regulatory information also notes that severe swelling of the face, lips, or tongue (angioedema) is a rare, severe allergic risk associated with ACE inhibitor medicines.


Q: Can Fortekor be taken with aspirin?

Caution and monitoring are recommended when Fortekor is taken alongside high doses of Aspirin, as Aspirin acts as an NSAID (Non-Steroidal Anti-Inflammatory Drug). Official warnings indicate this combination may potentially reduce the blood pressure-lowering effect and may contribute to renal function deterioration.


Q: Does Fortekor affect a person's mood or energy levels?

Official safety documents list fatigue and lethargy (low energy) as rare adverse reactions. Changes to mood, such as feelings of anxiety or nervousness, are also noted in the broader safety profile of the ACE inhibitor class.


Q: What if a user has an allergic reaction to Fortekor?

Known hypersensitivity to Fortekor or its components is a strict contraindication for its use. Severe allergic reactions, such as angioedema (swelling of the face, lips, or tongue), are noted as a very rare risk associated with the drug class.


Q: Does Fortekor have to be taken at the same time every day?

The drug is prescribed for once-daily use, with an effect that lasts for 24 hours. To ensure a steady level of the medicine is maintained in the body, official guidance often recommends establishing a routine by taking the dose at a consistent time each day.


Q: What are the storage requirements for Fortekor tablets?

To maintain the stability and quality of the active ingredient, the tablets must be stored in the original outer carton and kept in a dry place. The maximum recommended storage temperature is 25 C to protect the medicine from moisture.


Q: Is the active substance in Fortekor available under other brand names?

Yes, the active substance in Fortekor, Benazepril hydrochloride, is marketed under other brand names, depending on the region and the specific formulation (e.g., whether it is a single-component or combination product).

How should Fortekor be stored and disposed of?

Fortekor's storage and disposal requirements are mandated by regulatory labeling to maintain product quality and safety.

Storage Conditions

Fortekor must be kept out of the sight and reach of children. The product generally requires storage not to exceed 25 C (for Fortekor Flavour and Fortekor Plus) and must be stored in a dry place. To protect the tablets from moisture, the blister packaging must remain in the original outer carton.

Stability and Handling

If a tablet is divided, the unused half must be returned to the blister space immediately. The stability period for these tablet halves is very limited, specifically 2 days for Fortekor Flavour and 1 day for Fortekor Plus.

Disposal Instructions

Unused or expired Fortekor should not be disposed of in household waste or wastewater. Disposal must follow local requirements, typically utilizing pharmaceutical take-back schemes or by returning the product to the veterinary surgeon.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fortekor found in:

A-Z Index: